{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T20:13:43Z","timestamp":1784837623789,"version":"3.55.0"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Critical Care"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jcrc.2026.155655","type":"journal-article","created":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T17:16:03Z","timestamp":1781457363000},"page":"155655","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Intensive care admissions for severe immune-related adverse events associated with immune checkpoint inhibitor therapy: a 10-year cohort study"],"prefix":"10.1016","volume":"95","author":[{"given":"Samuel","family":"Pichon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghadi","family":"Zebian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Lacombe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Mole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidwine","family":"Wemeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Ledoult","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed E.L.","family":"Kalioubie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Gaudet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Robriquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00f4me","family":"Bureau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Launay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9mentine","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Sobanski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mercedes","family":"Jourdain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcrc.2026.155655_bb0005","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/S1470-2045(18)30700-9","article-title":"Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial","volume":"19","author":"Hodi","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jcrc.2026.155655_bb0010","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.jcrc.2026.155655_bb0015","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-related adverse events with immune checkpoint blockade: a comprehensive review","volume":"54","author":"Michot","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jcrc.2026.155655_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102536","article-title":"Clinical spectrum and evolution of immune-checkpoint inhibitors toxicities over a decade\u2014a worldwide perspective","volume":"70","author":"Gougis","year":"2024","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.jcrc.2026.155655_bb0025","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/j.cell.2021.02.011","article-title":"Understanding and treating the inflammatory adverse events of cancer immunotherapy","volume":"184","author":"Dougan","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.jcrc.2026.155655_bb0030","doi-asserted-by":"crossref","DOI":"10.1007\/s00134-025-08155-x","article-title":"Life-threatening immune-related adverse events in the intensive care unit: a narrative review","author":"Pichon","year":"2025","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.jcrc.2026.155655_bb0035","doi-asserted-by":"crossref","DOI":"10.1186\/s13613-023-01122-z","article-title":"ICU admission for solid cancer patients treated with immune checkpoint inhibitors","volume":"13","author":"Toffart","year":"2023","journal-title":"Ann Intensive Care"},{"key":"10.1016\/j.jcrc.2026.155655_bb0040","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.7302","article-title":"Treatment patterns and survival outcomes of patients admitted to the intensive care unit due to immune-related adverse events of immune checkpoint inhibitors","volume":"13","author":"Lin","year":"2024","journal-title":"Cancer Med"},{"key":"10.1016\/j.jcrc.2026.155655_bb0045","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s13613-020-00761-w","article-title":"Immune-related adverse events: a retrospective look into the future of oncology in the intensive care unit","volume":"10","author":"Joseph","year":"2020","journal-title":"Ann Intensive Care"},{"key":"10.1016\/j.jcrc.2026.155655_bb0050","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1097\/COC.0000000000000935","article-title":"Severe immune checkpoint inhibitor toxicity leading to ICU admission in patients with solid Tumors","volume":"45","author":"Leprince","year":"2022","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.jcrc.2026.155655_bb0055","doi-asserted-by":"crossref","first-page":"190012","DOI":"10.1183\/16000617.0012-2019","article-title":"Management of pulmonary toxicity associated with immune checkpoint inhibitors","volume":"28","author":"Delaunay","year":"2019","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.jcrc.2026.155655_bb0060","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002890","article-title":"Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors","volume":"9","author":"Guidon","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jcrc.2026.155655_bb0065","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of Immune-Related Adverse Events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"JCO"},{"key":"10.1016\/j.jcrc.2026.155655_bb0070","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1053\/j.gastro.2020.08.063","article-title":"AGA clinical practice update on diagnosis and Management of Immune Checkpoint Inhibitor Colitis and Hepatitis: expert review","volume":"160","author":"Dougan","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jcrc.2026.155655_bb0075","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1161\/CIRCULATIONAHA.118.034497","article-title":"Myocarditis in the setting of Cancer therapeutics: proposed case definitions for emerging clinical syndromes in cardio-oncology","volume":"140","author":"Bonaca","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jcrc.2026.155655_bb0080","doi-asserted-by":"crossref","first-page":"339","DOI":"10.4143\/crt.2020.790","article-title":"The pattern of time to onset and resolution of immune-related adverse events caused by immune checkpoint inhibitors in Cancer: A pooled analysis of 23 clinical trials and 8,436 patients","volume":"53","author":"Tang","year":"2021","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.jcrc.2026.155655_bb0085","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006398","article-title":"Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology","volume":"11","author":"Naidoo","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jcrc.2026.155655_bb0090","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1002\/sim.7992","article-title":"Minimum sample size for developing a multivariable prediction model: PART II - binary and time-to-event outcomes","volume":"38","author":"Riley","year":"2019","journal-title":"Stat Med"},{"key":"10.1016\/j.jcrc.2026.155655_bb0095","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1002\/ijc.35347","article-title":"How many people in the US are eligible for and respond to checkpoint inhibitors: an empirical analysis","volume":"156","author":"Haslam","year":"2025","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jcrc.2026.155655_bb0100","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3390\/curroncol28010007","article-title":"Emergency department utilization for patients receiving immune checkpoint inhibitors: A retrospective analysis of identification and outcomes for those presenting for immune-related adverse events","volume":"28","author":"Holstead","year":"2020","journal-title":"Curr Oncol"},{"key":"10.1016\/j.jcrc.2026.155655_bb0105","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1093\/qjmed\/hcac258","article-title":"Intensive care unit requirements in patients treated with immune checkpoint inhibitors","volume":"116","author":"Cooksley","year":"2023","journal-title":"QJM"},{"key":"10.1016\/j.jcrc.2026.155655_bb0110","doi-asserted-by":"crossref","DOI":"10.1111\/liv.70264","article-title":"Breaking barriers for intensive care admission in patients with advanced HCC on immunotherapy","volume":"45","author":"Fortuny","year":"2025","journal-title":"Liver Int"},{"key":"10.1016\/j.jcrc.2026.155655_bb0115","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/CJI.0000000000000468","article-title":"Real-world outcomes of ipilimumab plus nivolumab combination therapy in a nation-wide cohort of advanced melanoma patients in the Netherlands","volume":"46","author":"Van Zeijl","year":"2023","journal-title":"J Immunother"},{"key":"10.1016\/j.jcrc.2026.155655_bb0120","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2020-217018","article-title":"Rheumatic disorders associated with immune checkpoint inhibitors: what about myositis? An analysis of the WHO\u00e2\u20ac\u2122s adverse drug reactions database","volume":"81","author":"Nguy\u011bn","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jcrc.2026.155655_bb0125","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.neurol.2023.03.029","article-title":"Evaluation of a self-questionnaire to screen for neurological complications associated with immunological checkpoint inhibitors: are we missing something?","volume":"179","author":"Lemarchant","year":"2023","journal-title":"Rev Neurol (Paris)"},{"key":"10.1016\/j.jcrc.2026.155655_bb0130","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.3389\/fonc.2020.01785","article-title":"Pneumonitis induced by immune checkpoint inhibitors: from clinical data to translational investigation","volume":"10","author":"Zhu","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.jcrc.2026.155655_bb0135","doi-asserted-by":"crossref","DOI":"10.1172\/JCI170503","article-title":"Pulmonary toxicity of immune checkpoint immunotherapy","volume":"134","author":"Ghanbar","year":"2024","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jcrc.2026.155655_bb0140","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: A systematic review and Meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jcrc.2026.155655_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102586","article-title":"Immune checkpoint inhibitor-induced myositis, the earliest and most lethal complication among rheumatic and musculoskeletal toxicities","volume":"19","author":"Allenbach","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jcrc.2026.155655_bb0150","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/s41574-021-00484-3","article-title":"Endocrine toxicities of immune checkpoint inhibitors","volume":"17","author":"Wright","year":"2021","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.jcrc.2026.155655_bb0155","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007409","article-title":"Corticosteroid-resistant immune-related adverse events: a systematic review","volume":"12","author":"Daetwyler","year":"2024","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jcrc.2026.155655_bb0160","doi-asserted-by":"crossref","first-page":"3713","DOI":"10.1200\/JCO.24.00191","article-title":"Corticosteroids for immune-related adverse events and checkpoint inhibitor efficacy: analysis of six clinical trials","volume":"42","author":"Verheijden","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jcrc.2026.155655_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114172","article-title":"Corticosteroids and other immunosuppressants for immune-related adverse events and checkpoint inhibitor effectiveness in melanoma","volume":"207","author":"Verheijden","year":"2024","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jcrc.2026.155655_bb0170","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1016\/j.jtho.2021.06.024","article-title":"Beyond steroids: immunosuppressants in steroid-refractory or resistant immune-related adverse events","volume":"16","author":"Luo","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jcrc.2026.155655_bb0175","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1158\/2159-8290.CD-22-1180","article-title":"Abatacept\/Ruxolitinib and screening for concomitant respiratory muscle failure to mitigate fatality of immune-checkpoint inhibitor myocarditis","volume":"13","author":"Salem","year":"2023","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jcrc.2026.155655_bb0180","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004699","article-title":"Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept","volume":"10","author":"Nguyen","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jcrc.2026.155655_bb0185","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1056\/NEJMc1901677","article-title":"Abatacept for Severe Immune Checkpoint Inhibitor\u2013Associated Myocarditis","volume":"380","author":"Salem","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcrc.2026.155655_bb0190","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1158\/2159-8290.CD-20-0856","article-title":"A Genetic Mouse Model Recapitulates Immune Checkpoint Inhibitor\u2013Associated Myocarditis and Supports a Mechanism-Based Therapeutic Intervention","volume":"11","author":"Wei","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jcrc.2026.155655_bb0195","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.revmed.2024.10.452","article-title":"JAK inhibitors (JAKi): mechanisms of action and perspectives in systemic and autoimmune diseases","volume":"46","author":"Chikhoune","year":"2025","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.jcrc.2026.155655_bb0200","article-title":"Features of myositis and myasthenia gravis in patients treated with immune checkpoint inhibitors: a multicentric, retrospective cohort study","volume":"50","author":"Plomp","year":"2025","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.jcrc.2026.155655_bb0205","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study","volume":"19","author":"Salem","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jcrc.2026.155655_bb0210","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jcrc.2021.05.020","article-title":"Critically ill patients with severe immune checkpoint inhibitor related neurotoxicity: A multi-center case series","volume":"65","author":"Rajendram","year":"2021","journal-title":"J Crit Care"},{"key":"10.1016\/j.jcrc.2026.155655_bb0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114028","article-title":"Second-line therapies for steroid-refractory immune-related adverse events in patients treated with immune checkpoint inhibitors","volume":"203","author":"Ruf","year":"2024","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jcrc.2026.155655_bb0220","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001731","article-title":"Steroid-refractory PD-(L)1 pneumonitis: incidence, clinical features, treatment, and outcomes","volume":"9","author":"Balaji","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jcrc.2026.155655_bb0225","article-title":"Immune checkpoint inhibitor rechallenge after immune-related adverse events: a retrospective study from VigiBase update in 2024 looking for emergent safety signals","volume":"14","author":"L\u2019Orphelin","year":"2024","journal-title":"BMJ Open"},{"key":"10.1016\/j.jcrc.2026.155655_bb0230","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1001\/jamaoncol.2020.0726","article-title":"Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with Cancer","volume":"6","author":"Dolladille","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jcrc.2026.155655_bb0235","doi-asserted-by":"crossref","first-page":"e1425","DOI":"10.1093\/oncolo\/oyae134","article-title":"Safety, efficacy, and survival outcomes of immune checkpoint inhibitors rechallenge in patients with cancer: a systematic review and meta-analysis","volume":"29","author":"Liu","year":"2024","journal-title":"Oncologist"},{"key":"10.1016\/j.jcrc.2026.155655_bb0240","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001622","article-title":"Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade \u22652 immune-related adverse events in patients with cancer","volume":"8","author":"Allouchery","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jcrc.2026.155655_bb0245","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.704475","article-title":"The prognostic significance of the continuous Administration of Anti-PD-1 antibody via continuation or rechallenge after the occurrence of immune-related adverse events","volume":"11","author":"Fujisaki","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.jcrc.2026.155655_bb0250","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1093\/annonc\/mdx642","article-title":"Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma","volume":"29","author":"Pollack","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jcrc.2026.155655_bb0255","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1001\/jamaoncol.2019.1022","article-title":"Evaluation of Readministration of immune checkpoint inhibitors after immune-related adverse events in patients with Cancer","volume":"5","author":"Simonaggio","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jcrc.2026.155655_bb0260","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.730320","article-title":"Safety and efficacy of the rechallenge of immune checkpoint inhibitors after immune-related adverse events in patients with Cancer: A systemic review and Meta-analysis","volume":"12","author":"Zhao","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcrc.2026.155655_bb0265","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1403658","article-title":"Safety of immune checkpoint inhibitor rechallenge after severe immune-related adverse events: a retrospective analysis","volume":"14","author":"Eldani","year":"2024","journal-title":"Front Oncol"},{"key":"10.1016\/j.jcrc.2026.155655_bb0270","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.jaccao.2025.02.004","article-title":"Rechallenge after severe immune checkpoint inhibitor myocarditis","volume":"7","author":"Bailly","year":"2025","journal-title":"JACC CardioOncology"},{"key":"10.1016\/j.jcrc.2026.155655_bb0275","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000604","article-title":"Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy","volume":"8","author":"Haanen","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jcrc.2026.155655_bb0280","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s13613-024-01366-3","article-title":"Factors associated with cancer treatment resumption after ICU stay in patients with solid tumors","volume":"14","author":"Benguerfi","year":"2024","journal-title":"Ann Intensive Care"},{"key":"10.1016\/j.jcrc.2026.155655_bb0285","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1001\/jamaoncol.2022.7711","article-title":"Association of immune-related adverse events with efficacy of atezolizumab in patients with non\u2013small cell lung cancer: pooled analyses of the Phase 3 IMpower130, IMpower132, and IMpower150 Randomized Clinical Trials","volume":"9","author":"Socinski","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jcrc.2026.155655_bb0290","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920980546","article-title":"The association between immune-related adverse events and the prognosis of solid cancer patients treated with immunotherapy: a systematic review and meta-analysis","volume":"12","author":"Xu","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.jcrc.2026.155655_bb0295","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2217\/imt-2020-0179","article-title":"Immortal time bias in the association between toxicity and response for immune checkpoint inhibitors: a meta-analysis","volume":"13","author":"Dall\u2019Olio FG, Rizzo A, Mollica V, Massucci M, Maggio I, Massari F.","year":"2021","journal-title":"Immunotherapy"},{"key":"10.1016\/j.jcrc.2026.155655_bb0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102452","article-title":"Analysis of the association between prospectively collected immune-related adverse events and survival in patients with solid tumor treated with immune-checkpoint blockers, taking into account immortal-time bias","volume":"110","author":"Kfoury","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.jcrc.2026.155655_bb0305","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41698-023-00380-1","article-title":"Immunosuppression for immune-related adverse events during checkpoint inhibition: an intricate balance","volume":"7","author":"Verheijden","year":"2023","journal-title":"npj Precis Onc"},{"key":"10.1016\/j.jcrc.2026.155655_bb0310","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002535","article-title":"Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis","volume":"9","author":"Tarhini","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jcrc.2026.155655_bb0315","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1007\/s00262-020-02803-5","article-title":"Immune-related adverse events: promising predictors for efficacy of immune checkpoint inhibitors","volume":"70","author":"Zhong","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.jcrc.2026.155655_bb0320","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s41422-018-0012-z","article-title":"Uncoupling therapeutic from immunotherapy-related adverse effects for safer and effective anti-CTLA-4 antibodies in CTLA4 humanized mice","volume":"28","author":"Du","year":"2018","journal-title":"Cell Res"},{"key":"10.1016\/j.jcrc.2026.155655_bb0325","doi-asserted-by":"crossref","first-page":"eabm5663","DOI":"10.1126\/scitranslmed.abm5663","article-title":"Soluble CTLA-4 mutants ameliorate immune-related adverse events but preserve efficacy of CTLA-4- and PD-1-targeted immunotherapy","volume":"15","author":"Liu","year":"2023","journal-title":"Sci Transl Med"}],"container-title":["Journal of Critical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0883944126002339?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0883944126002339?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T19:45:15Z","timestamp":1784835915000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0883944126002339"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":65,"alternative-id":["S0883944126002339"],"URL":"https:\/\/doi.org\/10.1016\/j.jcrc.2026.155655","relation":{},"ISSN":["0883-9441"],"issn-type":[{"value":"0883-9441","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intensive care admissions for severe immune-related adverse events associated with immune checkpoint inhibitor therapy: a 10-year cohort study","name":"articletitle","label":"Article Title"},{"value":"Journal of Critical Care","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcrc.2026.155655","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"155655"}}